Kim M Linton

15PUBLICATIONS

137CO-AUTHORS

Gene and molecular therapyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (15)

Sort by Publication Date:

|Jul 10, 2026

MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL.

|Jan 06, 2026

Juan Pablo Alderuccio, Diva Baggio, Sunwoo Han

|Sep 08, 2025

Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.

Lorenzo Falchi, Anna Sureda, Sirpa Leppä

|Sep 08, 2025

CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.

Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli

|Jun 05, 2025

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.

Alexey V Danilov, Swetha Kambhampati Thiruvengadam, Kim Linton

|Jan 27, 2025

Frontline treatment of follicular lymphoma: what will it take to change current practice?

Emmanuel Bachy, Kim Linton

Pageof 3

Frequent Collaborators

Pamela McKay

Jessica Okosun

Andrew J Davies

Christopher P Fox

Toby A Eyre

Rohan Shotton

Anna Sureda

Graham P Collins

Tobias Menne

Sunil Iyengar

Frequent Collaborators

Pamela McKay

Jessica Okosun

Andrew J Davies

Christopher P Fox